Skip to content

ImmunityBio

US · IBRX #1397 by market cap Listed 1970
9.75 +0.06 +0.62%
Live - 5344 symbols - heartbeat 384s ago · 2026-10-08 07:37
Pre-market 9.65 -1.03%
After-hours 9.77 +0.16%
Overnight 9.70 -0.51%
Market cap
10.33B
P/B
-9.87
EPS
-0.38
Reader sentiment Are you bullish or bearish on IBRX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/2/19
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/3/4
  • Form 144 | ImmunityBio(IBRX.US) Officer Proposes to Sell 7.66 Million in Common Stocks
    Market Newswire · 2026/10/5
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2026/3/12
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $5
    Market Newswire · 2025/12/15
  • H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/8/5
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $9
    Market Newswire · 2026/1/23
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/2/3
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/1/26
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Cuts Target Price to $12
    Market Newswire · 2026/5/8
  • Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/9/8
  • Rating change
    BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/3/25
  • BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/8/5
  • Rating change
    ImmunityBio (IBRX) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/5/8
  • Rating change
    Jefferies Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $9
    Market Newswire · 2025/12/13
  • Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, Vs. FactSet Est of $0.08 Loss
    MT Newswires · 2026/8/4
  • Rating change
    H.C. Wainwright Sticks to Its Buy Rating for ImmunityBio (IBRX)
    TipRanks · 2026/4/30
  • Rating change
    Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $7
    Market Newswire · 2026/1/20
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/2/24
  • Rating change
    H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/1/20

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:37:04 · For reference only, not investment advice and not tailored to your situation.